53 results on '"Linton, MacRae F."'
Search Results
2. Longitudinal low density lipoprotein cholesterol goal achievement and cardiovascular outcomes among adult patients with familial hypercholesterolemia: The CASCADE FH registry
- Author
-
Duell, P. Barton, Gidding, Samuel S., Andersen, Rolf L., Knickelbine, Thomas, Anderson, Lars, Gianos, Eugenia, Shrader, Peter, Kindt, Iris, O'Brien, Emily C., McCann, Dervilla, Hemphill, Linda C., Ahmed, Catherine D., Martin, Seth S., Larry, John A., Ahmad, Zahid S., Kullo, Iftikhar J., Underberg, James A., Guyton, John, Thompson, Paul, Wilemon, Katherine, Roe, Matthew T., Rader, Daniel J., Cuchel, Marina, Linton, MacRae F., Shapiro, Michael D., Moriarty, Patrick M., and Knowles, Joshua W.
- Published
- 2019
- Full Text
- View/download PDF
3. Dual inhibition of endothelial miR-92a-3p and miR-489-3p reduces renal injury-associated atherosclerosis
- Author
-
Wiese, Carrie B., Zhong, Jianyong, Xu, Zhi-Qi, Zhang, Youmin, Ramirez Solano, Marisol A., Zhu, Wanying, Linton, MacRae F., Sheng, Quanhu, Kon, Valentina, and Vickers, Kasey C.
- Published
- 2019
- Full Text
- View/download PDF
4. Health disparities among adult patients with a phenotypic diagnosis of familial hypercholesterolemia in the CASCADE-FH™ patient registry
- Author
-
Amrock, Stephen M., Duell, P. Barton, Knickelbine, Thomas, Martin, Seth S., O'Brien, Emily C., Watson, Karol E., Mitri, Joanna, Kindt, Iris, Shrader, Peter, Baum, Seth J., Hemphill, Linda C., Ahmed, Catherine D., Andersen, Rolf L., Kullo, Iftikhar J., McCann, Dervilla, Larry, John A., Murray, Michael F., Fishberg, Robert, Guyton, John R., Wilemon, Katherine, Roe, Matthew T., Rader, Daniel J., Ballantyne, Christie M., Underberg, James A., Thompson, Paul, Duffy, Dannielle, Linton, MacRae F., Shapiro, Michael D., Moriarty, Patrick M., Knowles, Joshua W., and Ahmad, Zahid S.
- Published
- 2017
- Full Text
- View/download PDF
5. Absence of regulated splicing of fibronectin EDA exon reduces atherosclerosis in mice
- Author
-
Babaev, Vladimir R., Porro, Fabiola, Linton, MacRae F., Fazio, Sergio, Baralle, Francisco E., and Muro, Andrés F.
- Published
- 2008
- Full Text
- View/download PDF
6. Children with Heterozygous Familial Hypercholesterolemia in the United States: Data from the Cascade Screening for Awareness and Detection-FH Registry.
- Author
-
de Ferranti, Sarah D., Shrader, Peter, Linton, MacRae F., Knowles, Joshua W., Hudgins, Lisa C., Benuck, Irwin, Kindt, Iris, O'Brien, Emily C., Peterson, Amy L., Ahmad, Zahid S., Clauss, Sarah, Duell, P. Barton, Shapiro, Michael D., Wilemon, Katherine, Gidding, Samuel S., and Neal, William
- Abstract
Objective: To describe enrollment characteristics of youth in the Cascade Screening for Awareness and Detection of FH Registry.Study Design: This is a cross-sectional analysis of 493 participants aged <18 years with heterozygous familial hypercholesterolemia recruited from US lipid clinics (n = 20) between April 1, 2014, and January 12, 2018. At enrollment, some were new patients and some were already in care. Clinical characteristics are described, including lipid levels and lipid-lowering treatments.Results: Mean age at diagnosis was 9.4 (4.0) years; 47% female, 68% white and 12% Hispanic. Average (SD) highest Low-density lipoprotein cholesterol (LDL-C) was 238 (61) mg/dL before treatment. Lipid-lowering therapy was used by 64% of participants; 56% were treated with statin. LDL-C declined 84 mg/dL (33%) among those treated with lipid-lowering therapy; statins produced the greatest decline, 100 mg/dL (39% reduction). At enrollment, 39% had reached an LDL-C goal, either <130 mg/dL or ≥50% decrease from pre-treatment; 20% of those on lipid-lowering therapy reached both goals.Conclusions: Among youth enrolled in the Cascade Screening for Awareness and Detection of FH Registry, diagnosis occurred relatively late, only 77% of children eligible for lipid-lowering therapy were receiving treatment, and only 39% of those treated met their LDL-C goal. Opportunities exist for earlier diagnosis, broader use of lipid-lowering therapy, and greater reduction of LDL-C levels. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
7. JCL roundtable: Lipids and inflammation in atherosclerosis.
- Author
-
Bornfeldt, Karin E., Linton, MacRae F., Fisher, Edward A., and Guyton, John R.
- Subjects
CARDIOVASCULAR disease treatment ,APOLIPOPROTEINS ,ATHEROSCLEROSIS ,GENE expression ,HIGH density lipoproteins ,INFLAMMATION ,LIPIDS ,LOW density lipoproteins ,MICRORNA - Abstract
Clinical effort in lipidology focuses largely on mitigating effects of atherosclerosis, a pathologic process localized to the intimal layer of larger arteries. This JCL Roundtable brings together 3 leading researchers to discuss the current understanding of pathogenesis in atherosclerosis. We begin by recognizing that low density lipoprotein concentrations in arterial intima far exceed concentrations in other connective tissues, consistent with the response-to-retention hypothesis of atherogenesis. High density lipoproteins facilitate reverse cholesterol transport and also have antioxidant and anti-inflammatory roles. New evidence points to remnants of triglyceride-rich lipoproteins as promoters of atherogenesis, highlighted by deleterious effects of apolipoprotein C-III. The multifaceted role of inflammation is becoming clearer through discoveries related to leukocyte recruitment, efferocytosis, resolution of inflammation, and crystal formation. MicroRNAs represent a new, complex mode of gene regulation bearing on lipoprotein and inflammation biology. Progress in understanding atherosclerosis portends a future in which residual risk related to obesity, diabetes, and other factors will yield to new targeted therapies. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
8. Progressively decreasing plasma high-density lipoprotein cholesterol levels preceding diagnosis of smoldering myeloma.
- Author
-
Tavori, Hagai, Ormseth, Michelle J., Lilley, Jessica S., Papen, Courtney R., May-Zhang, Linda S., Davies, Sean S., Linton, MacRae F., and Fazio, Sergio
- Subjects
APOLIPOPROTEINS ,AUTOANTIBODIES ,CENTRIFUGATION ,HIGH density lipoproteins ,HYPERGAMMAGLOBULINEMIA ,HYPERLIPIDEMIA ,NUCLEAR magnetic resonance spectroscopy ,AUTOANALYZERS - Abstract
We report a case of disappearing high-density lipoprotein (HDL) syndrome caused by oxidative modification of HDL and by autoantibodies against modified HDL, with subsequent diagnosis of myeloma. An elderly Caucasian man had normal lipid levels with HDL cholesterol (HDL-C) levels in the upper 70 mg/dL range from 1999 to 2003. In 2003, his HDL-C levels began to progressively fall, and by 2011, they were undetectable (<5 mg/dL) when measured with a Beckman Synchron LX auto analyzer. Analyses of the plasma sample from 2011 using ultracentrifugation (Vertical Auto Profile), nuclear magnetic resonance, and Ace EXCEL auto analyzer have shown that HDL-C levels were easily detectable (47–54 mg/dL), although reduced compared with his pre-2003 values. Analyses of his plasma sample from 2011 also showed the presence of lipid-adducted apolipoprotein A1 (apoA1) and high titer of antibodies against the adducted apoA1. Interestingly, a negative correlation between HDL-C levels and the titer of antibodies against apoA1 adducts was found in the control cohort. Finally, we show that in the mouse system, an antibody against apoA1 increases the clearance of HDL from plasma. This case of smoldering myeloma preceded by acquired, severe HDL-C deficiency, likely because of oxidative modifications of the HDL protein leading to the formation of autoantibodies, interference with clinical measurement of HDL-C, and increased plasma clearance of HDL, adds to the list of diagnostic considerations for unexplained HDL-C decreases over time. • Severe high-density lipoprotein (HDL) cholesterol (HDL-C) deficiency not because of genetic mutations is rare and often artifactual. • Isolevuglandins are immunogenic lipid oxidation species that can form on HDL. • Immune complexes on HDL may alter their plasma clearance. • Paraproteinemia can affect methods of detection of HDL-C. • This case adds myeloma differential diagnoses for a large unexplained drop in HDL-C. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
9. Hepatocyte estrogen receptor alpha mediates estrogen action to promote reverse cholesterol transport during Western-type diet feeding.
- Author
-
Zhu, Lin, Shi, Jeanne, Luu, Thao N., Neuman, Joshua C., Trefts, Elijah, Yu, Sophia, Palmisano, Brian T., Wasserman, David H., Linton, MacRae F., and Stafford, John M.
- Abstract
Objective Hepatocyte deletion of estrogen receptor alpha (LKO-ERα) worsens fatty liver, dyslipidemia, and insulin resistance in high-fat diet fed female mice. However, whether or not hepatocyte ERα regulates reverse cholesterol transport (RCT) in mice has not yet been reported. Methods and results Using LKO-ERα mice and wild-type (WT) littermates fed a Western-type diet, we found that deletion of hepatocyte ERα impaired in vivo RCT measured by the removal of 3 H-cholesterol from macrophages to the liver, and subsequently to feces, in female mice but not in male mice. Deletion of hepatocyte ERα decreased the capacity of isolated HDL to efflux cholesterol from macrophages and reduced the ability of isolated hepatocytes to accept cholesterol from HDL ex vivo in both sexes. However, only in female mice, LKO-ERα increased serum cholesterol levels and increased HDL particle sizes. Deletion of hepatocyte ERα increased adiposity and worsened insulin resistance to a greater degree in female than male mice. All of the changes lead to a 5.6-fold increase in the size of early atherosclerotic lesions in female LKO-ERα mice compared to WT controls. Conclusions Estrogen signaling through hepatocyte ERα plays an important role in RCT and is protective against lipid retention in the artery wall during early stages of atherosclerosis in female mice fed a Western-type diet. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
10. A case of severe acquired hypertriglyceridemia in a 7-year-old girl.
- Author
-
Lilley, Jessica S., Linton, MacRae F., Kelley, Jennifer C., Graham, T. Brent, Fazio, Sergio, and Tavori, Hagai
- Subjects
DRUG therapy for hyperlipidemia ,CHLOROQUINE ,AUTOANTIBODIES ,AUTOIMMUNE diseases ,ESTERASES ,HYPERLIPOPROTEINEMIA ,HYPOGLYCEMIA ,IMMUNOBLOTTING ,LOW-fat diet ,PANCREATITIS ,PREDNISONE ,SHOCK (Pathology) ,SJOGREN'S syndrome ,TRIGLYCERIDES ,THERAPEUTICS - Abstract
We report a case of severe type I hyperlipoproteinemia caused by autoimmunity against lipoprotein lipase (LPL) in the context of presymptomatic Sjögren's syndrome. A 7-year-old mixed race (Caucasian/African American) girl was admitted to the intensive care unit at Vanderbilt Children's Hospital with acute pancreatitis and shock. She was previously healthy aside from asthma and history of Hashimoto's thyroiditis. Admission triglycerides (TGs) were 2191 mg/dL but returned to normal during the hospital stay and in the absence of food intake. At discharge, she was placed on a low-fat, low-sugar diet. She did not respond to fibrates, prescription fish oil, metformin, or orlistat, and during the following 2 years, she was hospitalized several times with recurrent pancreatitis. Except for a heterozygous mutation in the promoter region of LPL, predicted to have no clinical significance, she had no further mutations in genes known to affect TG metabolism and to cause inherited type I hyperlipoproteinemia, such as APOA5, APOC2 , GPIHBP1 , or LMF1 . When her TG levels normalized after incidental use of prednisone, an autoimmune mechanism was suspected. Immunoblot analyses showed the presence of autoantibodies to LPL in the patient's plasma. Autoantibodies to LPL decreased by 37% while patient was on prednisone, and by 68% as she subsequently transitioned to hydroxychloroquine monotherapy. While on hydroxychloroquine, she underwent a supervised high-fat meal challenge and showed normal ability to metabolize TG. For the past 3 years and 6 months, she has had TG consistently <250 mg/dL, and no symptoms of, or readmissions for, pancreatitis. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
11. Lipoprotein modulation of proteinuric renal injury.
- Author
-
Tsuchida, Yohei, Zhong, Jianyong, Otsuka, Tadashi, Dikalova, Anna, Pastan, Ira, Anantharamaiah, G. M., Linton, MacRae F., Yancey, Patricia G., Ikizler, T. Alp, Fogo, Agnes B., Yang, Haichun, and Kon, Valentina
- Published
- 2019
- Full Text
- View/download PDF
12. SR-BI: A Multifunctional Receptor in Cholesterol Homeostasis and Atherosclerosis.
- Author
-
Linton, MacRae F., Tao, Huan, Linton, Edward F., and Yancey, Patricia G.
- Subjects
- *
CHOLESTEROL in the body , *HOMEOSTASIS , *ATHEROSCLEROSIS , *HIGH density lipoproteins , *PROTEIN metabolism - Abstract
The HDL receptor scavenger receptor class B type I (SR-BI) plays crucial roles in cholesterol homeostasis, lipoprotein metabolism, and atherosclerosis. Hepatic SR-BI mediates reverse cholesterol transport (RCT) by the uptake of HDL cholesterol for routing to the bile. Through the selective uptake of HDL lipids, hepatic SR-BI modulates HDL composition and preserves HDL’s atheroprotective functions of mediating cholesterol efflux and minimizing inflammation and oxidation. Macrophage and endothelial cell SR-BI inhibits the development of atherosclerosis by mediating cholesterol trafficking to minimize atherosclerotic lesion foam cell formation. SR-BI signaling also helps limit inflammation and cell death and mediates efferocytosis of apoptotic cells in atherosclerotic lesions thereby preventing vulnerable plaque formation. SR-BI is emerging as a multifunctional therapeutic target to reduce atherosclerosis development. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
13. Scavenging dicarbonyls with 5′-O-pentyl-pyridoxamine increases HDL net cholesterol efflux capacity and attenuates atherosclerosis and insulin resistance.
- Author
-
Huang, Jiansheng, Tao, Huan, Yancey, Patricia G., Leuthner, Zoe, May-Zhang, Linda S., Jung, Ju-Yang, Zhang, Youmin, Ding, Lei, Amarnath, Venkataraman, Liu, Dianxin, Collins, Sheila, Davies, Sean S., and Linton, MacRae F.
- Abstract
Oxidative stress contributes to the development of insulin resistance (IR) and atherosclerosis. Peroxidation of lipids produces reactive dicarbonyls such as Isolevuglandins (IsoLG) and malondialdehyde (MDA) that covalently bind plasma/cellular proteins, phospholipids, and DNA leading to altered function and toxicity. We examined whether scavenging reactive dicarbonyls with 5′-O-pentyl-pyridoxamine (PPM) protects against the development of IR and atherosclerosis in Ldlr
−/− mice. Male or female Ldlr−/− mice were fed a western diet (WD) for 16 weeks and treated with PPM versus vehicle alone. Plaque extent, dicarbonyl-lysyl adducts, efferocytosis, apoptosis, macrophage inflammation, and necrotic area were measured. Plasma MDA-LDL adducts and the in vivo and in vitro effects of PPM on the ability of HDL to reduce macrophage cholesterol were measured. Blood Ly6Chi monocytes and ex vivo 5-ethynyl-2′-deoxyuridine (EdU) incorporation into bone marrow CD11b+ monocytes and CD34+ hematopoietic stem and progenitor cells (HSPC) were also examined. IR was examined by measuring fasting glucose/insulin levels and tolerance to insulin/glucose challenge. PPM reduced the proximal aortic atherosclerosis by 48% and by 46% in female and male Ldlr−/− mice, respectively. PPM also decreased IR and hepatic fat and inflammation in male Ldlr−/− mice. Importantly, PPM decreased plasma MDA-LDL adducts and prevented the accumulation of plaque MDA- and IsoLG-lysyl adducts in Ldlr−/− mice. In addition, PPM increased the net cholesterol efflux capacity of HDL from Ldlr−/− mice and prevented both the in vitro impairment of HDL net cholesterol efflux capacity and apoAI crosslinking by MPO generated hypochlorous acid. Moreover, PPM decreased features of plaque instability including decreased proinflammatory M1-like macrophages, IL-1β expression, myeloperoxidase, apoptosis, and necrotic core. In contrast, PPM increased M2-like macrophages, Tregs, fibrous cap thickness, and efferocytosis. Furthermore, PPM reduced inflammatory monocytosis as evidenced by decreased blood Ly6Chi monocytes and proliferation of bone marrow monocytes and HSPC from Ldlr−/− mice. PPM has pleotropic atheroprotective effects in a murine model of familial hypercholesterolemia, supporting the therapeutic potential of reactive dicarbonyl scavenging in the treatment of IR and atherosclerotic cardiovascular disease. [Display omitted] • Reactive dicarbonyl scavenging with PPM prevents atherosclerosis in Ldlr−/− mice. • PPM improves insulin sensitivity and decreases hepatic fat in male Ldlr−/− mice. • PPM increases the net cholesterol capacity of HDL from Ldlr−/− mice. • PPM promotes plaque stability as evidenced by increased efferocytosis, Tregs, and collagen. • PPM prevents monocytosis by impairing CD11b+ monocyte and CD34+HSPC proliferation. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
14. Dysfunctional high-density lipoproteins in children with chronic kidney disease.
- Author
-
Kaseda, Ryohei, Jabs, Kathy, Hunley, Tracy E., Jones, Deborah, Bian, Aihua, Allen, Ryan M., Vickers, Kasey C., Yancey, Patricia G., Linton, MacRae F., Fazio, Sergio, and Kon, Valentina
- Subjects
HIGH density lipoproteins ,CHRONIC kidney failure in children ,HEMODIALYSIS ,KIDNEY function tests ,GENE expression - Abstract
Objectives Our aim was to determine if chronic kidney disease (CKD) occurring in childhood impairs the normally vasoprotective functions of high-density lipoproteins (HDLs). Materials and methods HDLs were isolated from children with end-stage renal disease on dialysis (ESRD), children with moderate CKD and controls with normal kidney function. Macrophage response to HDLs was studied as expression of inflammatory markers (MCP-1, TNF-α, IL-1β) and chemotaxis. Human umbilical vein endothelial cells were used for expression of adhesion molecules (ICAM-1, VCAM-1, E-selectin) and adhesion. Cellular proliferation, apoptosis, and necrosis of endothelial cells were measured by MTS/PMS reagent-based assay, flow cytometry, and ELISA. Cholesterol efflux was assessed by gas chromatographic measurements of cholesterol in macrophages exposed to HDLs. Results Compared with HDL Control , HDL CKD and HDL ESRD heightened the cytokine response and disrupted macrophage chemotaxis. HDL Control reduced endothelial expression of ICAM-1, VCAM-1, E-selectin, whereas HDL CKD and HDL ESRD were less effective and showed reduced capacity to protect endothelial cells against monocyte adhesion. Compared with a dramatically enhanced endothelial proliferation following injurious stimulus by HDL Control , neither HDL CKD nor HDL ESRD caused proliferative effects. HDLs of all three groups were equally protective against apoptosis assessed by flow cytometry and cleaved caspase-3 activity. Compared to HDL Control , HDL CKD and HDL ESRD trended toward reduced capacity as cholesterol acceptors. Conclusion CKD in children impairs HDL function. Even in the absence of long-standing and concomitant risk factors, CKD alters specific HDL functions linked to control of inflammation and endothelial responses. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
15. High-density lipoprotein therapeutics and cardiovascular prevention.
- Author
-
Fazio, Sergio and Linton, MacRae F.
- Subjects
HIGH density lipoproteins ,CARDIOVASCULAR disease prevention ,EPIDEMIOLOGY ,CLINICAL trials ,NIACIN ,APOLIPOPROTEINS ,CHOLESTEROL ,CHEMICAL inhibitors - Abstract
Abstract: The field of cardiovascular prevention has long anticipated the evolution of high-density lipoprotein (HDL) therapy from unproven metabolic tweaking to pillar of risk reduction on par with low-density lipoprotein control. However, the convincing epidemiologic data linking HDL cholesterol (HDL-C) and cardiovascular disease risk in an inverse correlation has not yet translated into clinical trial evidence supporting linearity between HDL-C increases and risk reduction, or identifying obvious goals of therapy. Although HDL-C-increasing lifestyle maneuvers and established HDL drugs such as niacin and fibrates are likely to protect the vasculature, the negative results obtained in trials of a cholesteryl ester transfer protein inhibitor remind us that HDL-C increases are not always beneficial. It is becoming clear that a functional HDL is a more desirable target than simply increasing HDL-C levels. The larger objective of improving HDL functionality (with or without HDL-C level changes) is bound to become the guiding principle for pharmaceutical research in this area. Several new compounds currently being tested bridge the classical aim of increasing HDL-C levels with the novel target of improving HDL function. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
16. Macrophage EP4 Deficiency Increases Apoptosis and Suppresses Early Atherosclerosis.
- Author
-
Babaev, Vladimir R., Chew, Joshua D., Ding, Lei, Davis, Sarah, Breyer, Matthew D., Breyer, Richard M., Oates, John A., Fazio, Sergio, and Linton, MacRae F.
- Subjects
ATHEROSCLEROSIS ,LIVER cells ,RETICULO-endothelial system ,KILLER cells - Abstract
Summary: Prostaglandin (PG) E
2 , a major product of activated macrophages, has been implicated in atherosclerosis and plaque rupture. The PGE2 receptors, EP2 and EP4, are expressed in atherosclerotic lesions and are known to inhibit apoptosis in cancer cells. To examine the roles of macrophage EP4 and EP2 in apoptosis and early atherosclerosis, fetal liver cell transplantation was used to generate LDLR−/− mice chimeric for EP2−/− or EP4−/− hematopoietic cells. After 8 weeks on a Western diet, EP4−/− → LDLR−/− mice, but not EP2−/− → LDLR−/− mice, had significantly reduced aortic atherosclerosis with increased apoptotic cells in the lesions. EP4−/− peritoneal macrophages had increased sensitivity to proapoptotic stimuli, including palmitic acid and free cholesterol loading, which was accompanied by suppression of activity of p-Akt, p-Bad, and NF-κB-regulated genes. Thus, EP4 deficiency inhibits the PI3K/Akt and NF-κB pathways compromising macrophage survival and suppressing early atherosclerosis, identifying macrophage EP4-signaling pathways as molecular targets for modulating the development of atherosclerosis. [Copyright &y& Elsevier]- Published
- 2008
- Full Text
- View/download PDF
17. Evidence of metabolic syndrome in lean children with premature pubarche at diagnosis.
- Author
-
Mathew, Revi P., Byrne, Daniel W., Linton, MacRae F., Vaughan, Douglas E., Fazio, Sergio, and Russell, William E.
- Subjects
METABOLIC syndrome ,INSULIN resistance ,ANTHROPOMETRY ,CYTOKINES - Abstract
Abstract: We investigated for evidence of early metabolic syndrome irrespective of body mass index (BMI) in subjects with premature pubarche (PP). Ten children with PP were compared with controls matched for age, sex, ethnicity, and BMI. Congenital adrenal hyperplasia and other known causes of PP were excluded by standard methods. Anthropometry, blood pressure (BP), dual-energy x-ray absorptiometry body scan, fasting blood lipid profile, and cytokines were obtained. The children were divided into 2 groups: (1) the total group of children with PP, and their age-, sex-, ethnicity-, and BMI-matched controls and (2) those with PP and normal BMI (<19 kg/m
2 ) and their matched controls selected from the original groups. The PP subjects with normal BMI (S1 ) showed significantly higher systolic BP (P = .028), diastolic BP (P = .028), and mean arterial pressure (P = .018) compared with matched controls (C1 ). Nevertheless, for both groups, all the above parameters were statistically not significant when corrected for height. Fat distribution in PP subjects indicated significantly higher android (P = .047) and android-gynoid ratio (P = .013). Normal-BMI PP children had significantly higher android-gynoid ratio fat distribution compared with their matched controls (P = .037). Trunk fat percentage (p: 0.04) and trunk fat (grams) (P = .007) were significantly elevated in PP children compared with matched controls. Again, for both groups, all the above parameters were not statistically significant when corrected for height. The PP subjects had significantly higher tumor necrosis factor (TNF)–α (P = .038) and interleukin-8 (picograms per milliliter) (P = .05) compared with matched controls. Normal-BMI PP children also had higher TNF-α (P = .028) compared with matched controls. When corrected for height, TNF-α was higher in the total (P = .037) and normal-BMI (P = .043) PP children. Premature pubarche can be linked to markers of the metabolic syndrome in lean children. [Copyright &y& Elsevier]- Published
- 2008
- Full Text
- View/download PDF
18. Cyclooxygenase products and atherosclerosis.
- Author
-
Linton, MacRae F. and Fazio, Sergio
- Subjects
ATHEROSCLEROSIS ,CYCLOOXYGENASES ,PROSTAGLANDINS ,ARACHIDONIC acid ,G proteins ,THROMBOXANES - Abstract
Prostaglandins (PGs) and their specific receptors play critical roles in atherothrombosis. Produced from arachidonic acid via two cyclooxygenase (COX) isoforms, PGs mediate their actions via G-protein coupled receptors. Thromboxane (TX) A
2 is a vasoconstrictor and platelet agonist, prostacyclin (PGI2 ) is a vasodilator that inhibits platelet function, and PGE2 modulates inflammation. The cardioprotective effects of aspirin are attributed to inhibition of COX-1 mediated platelet TX production. In contrast, the selective COX-2 inhibitor, rofecoxib, was removed from the market due increased cardiovascular events. Studies of pharmacological modulation of PGs and genetic deletion of specific PG receptors in murine models have provided insights into their roles in atherosclerosis, but murine models have major limitations in addressing issues of plaque rupture and thrombosis. Nonselective COX inhibition, COX-1 inhibition, TP antagonism, and deletion of the TX receptor (TP) reduce atherosclerosis in murine models; yet, elimination of COX-1 or TP expression in bone marrow-derived cells does not reduce atherosclerosis, indicating that COX-1-mediated platelet TX production is not a major driving force in murine atherogenesis. The results of COX-2 inhibition on atherosclerosis have been mixed with studies showing increased, decreased or unchanged lesion area, suggesting that the impact of COX-2 inhibition may vary with lesion stage. However, COX-2 inhibition or COX-2 gene deletion have a profound ability to prevent angiotensin II-induced aneurysm formation in mice. A number of studies have shown that genetic deletion of the PGI2 receptor (IP) accelerates the vascular response to injury. However, the data do not support a “balance” between COX-2-derived PGI2 and COX-1-derived platelet TX as a critical determinant of atherogenesis. Genetic deletion of microsomal PGES-1, a synthase that produces PGE2 , reduces atherosclerosis, an effect attributed to increased PGI2 production. PGE2 modulates inflammation and may impact atherogenesis directly via a number of mechanisms. A more detailed understanding of the roles of PGs and their receptors in atherothrombosis may point to more specific targets for the prevention of atherosclerotic cardiovascular disease. [Copyright &y& Elsevier]- Published
- 2008
- Full Text
- View/download PDF
19. Physiological relevance of apolipoprotein E recycling: studies in primary mouse hepatocytes.
- Author
-
Zhu, Mei-ying, Hasty, Alyssa H., Harris, Carla, Linton, MacRae F., Fazio, Sergio, and Swift, Larry L.
- Subjects
APOLIPOPROTEIN E ,LIVER cells ,BONE marrow ,ISOPENTENOIDS - Abstract
Abstract: Studies in our laboratory have shown that a fraction of apolipoprotein (apo) E internalized by hepatocytes escapes degradation and is resecreted. Although the intracellular routing is not fully understood, our studies suggest that a portion of apoE recycles through the Golgi apparatus. Given the role of the Golgi apparatus in lipoprotein secretion and the fact that apoE modulates the hepatic secretion of very low-density lipoprotein, we hypothesized that recycling apoE has an effect on hepatic very low-density lipoprotein assembly and/or secretion. To test this hypothesis, apoE
−/− mice were transplanted with bone marrow from wild-type mice. In this model, extrahepatic (macrophage-derived) apoE is internalized by the hepatocytes in vivo and is resecreted when the hepatocytes are placed in culture. Unexpectedly, our studies demonstrate that recycling apoE has little effect on hepatic lipid content or hepatocyte triglyceride secretion. In addition, recycling apoE has little effect on the expression of enzymes and proteins involved in lipid synthesis as well as plasma lipoprotein apoproteins. We conclude that the physiological relevance of apoE recycling may not be related to cell-specific functions, such as lipoprotein assembly in the liver. Rather, recycling may provide a mechanism for modulating general cellular effects such as intracellular cholesterol transport or cholesterol efflux. [Copyright &y& Elsevier]- Published
- 2005
- Full Text
- View/download PDF
20. Cyclooxygenase-2 and inflammation in atherosclerosis
- Author
-
Linton, MacRae F and Fazio, Sergio
- Subjects
- *
EICOSANOIC acid derivatives , *CYCLOOXYGENASES , *ATHEROSCLEROSIS , *THROMBOSIS , *BLOOD platelet aggregation - Abstract
By regulating the production of eicosanoids, cyclooxygenase (COX) modulates processes contributing to atherosclerosis and thrombosis, including platelet aggregation and the local inflammatory response. COX-2, a key mediator of inflammation, is upregulated in activated monocyte/macrophages, suggesting that COX-2 inhibition might reduce atherogenesis through its anti-inflammatory effects. In mouse models, selective inhibition of COX-2 or its deletion in macrophages protects against early atherosclerosis. The discovery that macrophage COX-2 is downregulated by oxidized low-density lipoprotein and liver X receptors indicates coordinated and reciprocal control of cholesterol homeostasis and inflammatory pathways. Thus, the impact of macrophage COX-2 expression on atherogenesis might be attenuated in advanced lesions. Concerns have been raised that inhibition of COX-2 might promote thrombotic cardiovascular events by disturbing the balance between platelet thromboxane A2 and endothelial prostacyclin. However, meta-analyses of randomized trials have failed to show excess of cardiovascular events among patients on COX-2 inhibitors. Prospective randomized evaluation of the effects of selective COX-2 inhibitors on cardiovascular events is warranted. [Copyright &y& Elsevier]
- Published
- 2004
- Full Text
- View/download PDF
21. The inflamed plaque: cytokine production and cellular cholesterol balance in the vessel wall.
- Author
-
Fazio, Sergio, Linton, MacRae F., Fazio, S, and Linton, M F
- Subjects
- *
INFLAMMATION , *CHOLESTEROL , *ATHEROSCLEROSIS - Abstract
Although the concept that inflammation plays a role in the biology of atherosclerosis is now well accepted, the basic feature of the arterial lesion remains the accumulation of clusters of foam cells. These clusters are the consequence of the enhanced recruitment of monocytes in the vessel wall induced by the hyperlipidemia and of the disproportionate accumulation of lipids in the cytoplasm of macrophages deriving from monocytes. Ultimately, every molecular force and pathway with modulating activity over the developing lesion will have to act on a convergence point with factors regulating cholesterol balance in the macrophage. Consistent with this view is the recent report that cytokines, such as tumor necrosis factor-alpha, can influence the expression of the scavenger receptor, whereas interferon-gamma can inhibit adenosine triphosphate-binding cassette transporter-1, the main effector of cholesterol efflux in the peripheral cell. Conversely, recent data have shown that primary alterations in macrophage cholesterol balance, such as those produced by the total absence of acylcoenzyme A:cholesterol acyltransferase-1, may determine local changes compatible with the activation of inflammatory pathways. In this brief review, we discuss some of the convergence points between inflammation and cholesterol balance, and we highlight the additional therapeutic targets suggested by these new developments in vascular biology. [ABSTRACT FROM AUTHOR]
- Published
- 2001
- Full Text
- View/download PDF
22. Proprotein Convertase Subtilisin/Kexin Type 9 as Transducer of Physiologic Influences on Cellular Cholesterol: A Case for Resistin ⁎ [⁎] Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.
- Author
-
Fazio, Sergio and Linton, MacRae F.
- Published
- 2012
- Full Text
- View/download PDF
23. Low Levels of High-Density Lipoprotein Cholesterol Due to Lecithin:Cholesterol Acyltransferase Mutations Increase Carotid Atherosclerosis ⁎ [⁎] Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.
- Author
-
Fazio, Sergio and Linton, MacRae F.
- Published
- 2011
- Full Text
- View/download PDF
24. Diagnosing Familial Hypercholesterolemia (FH) in the United States: Results from the CASCADE FH Patient Registry*†.
- Author
-
Ahmad, Zahid, Newman, Connie B., O'Brien, Emily C., Shrader, Peter, deGoma, Emil M., Ahmed, Catherine, Moriarty, Patrick M., Linton, MacRae F., Shapiro, Michael D., Duell, Barton, Ballantyne, Christie M., Neal, William, Duffy, Danielle, Hudgins, Lisa C., Hemphill, Linda C., Underberg, James A., Watson, Karol E., Gidding, Samuel S., Baum, Seth J., and Wilemon, Katherine
- Subjects
FAMILIAL hypercholesterolemia ,DIAGNOSIS - Published
- 2015
- Full Text
- View/download PDF
25. Myeloid lineage cell-restricted insulin resistance protects apolipoproteinE-deficient mice against atherosclerosis.
- Author
-
Baumgartl, Julia, Baudler, Stephanie, Scherner, Maximilian, Babaev, Vladimir R., Makowski, Liza, Suttles, Jill, McDuffie, Marcia, Tobe, Kazuyuki, Kadowaki, Takashi, Fazio, Sergio, Kahn, C. Ronald, Hotamisligil, Gökhan S., Krone, Wilhelm, Linton, MacRae F., and Brüning, Jens C.
- Published
- 2006
- Full Text
- View/download PDF
26. Expression of P1 DNA in mammalian cells and transgenic mice
- Author
-
McCormick, Sally P.A., Linton, Macrae F., and Young, Stephen G.
- Published
- 1994
- Full Text
- View/download PDF
27. Elucidation of physico-chemical principles of high-density lipoprotein–small RNA binding interactions.
- Author
-
Michell, Danielle L., Allen, Ryan M., Cavnar, Ashley B., Contreras, Danielle M., Minzhi Yu, Semler, Elizabeth M., Massick, Clark, Raby, Chase A., Castleberry, Mark, Ramirez, Marisol A., Wanying Zhu, Linda May-Zhang, Ifrim, Anca, Carr, John Jeffrey, Terry, James G., Schwendeman, Anna, Davies, Sean S., Quanhu Sheng, Linton, MacRae F., and Vickers, Kasey C.
- Subjects
- *
DOUBLE-stranded RNA , *RNA , *TRANSFER RNA , *APOLIPOPROTEIN A , *NON-coding RNA , *HIGH density lipoproteins , *RNA modification & restriction - Abstract
Extracellular small RNAs (sRNAs) are abundant in many biofluids, but little is known about their mechanisms of transport and stability in RNase-rich environments. We previously reported that high-density lipoproteins (HDLs) in mice were enriched with multiple classes of sRNAs derived from the endogenous transcriptome, but also from exogenous organisms. Here, we show that human HDL transports tRNA-derived sRNAs (tDRs) from host and nonhost species, the profiles of which were found to be altered in human atherosclerosis. We hypothesized that HDL binds to tDRs through apolipoprotein A-I (apoA-I) and that these interactions are conferred by RNAspecific features. We tested this using microscale thermophoresis and electrophoretic mobility shift assays and found that HDL binds to tDRs and other single-stranded sRNAs with strong affinity but did not bind to double-stranded RNA or DNA. Furthermore, we show that natural and synthetic RNA modifications influenced tDR binding to HDL. We demonstrate that reconstituted HDL bound to tDRs only in the presence of apoA-I, and purified apoA-I alone were able to bind sRNA. Conversely, phosphatidylcholine vesicles did not bind tDRs. In summary, we conclude that HDL binds to singlestranded sRNAs likely through nonionic interactions with apoA-I. These results highlight binding properties that likely enable extracellular RNA communication and provide a foundation for future studies to manipulate HDL–sRNA interactions for therapeutic approaches to prevent or treat disease. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
28. The relationship between dose of vitamin E and suppression of oxidative stress in humans
- Author
-
Roberts, L. Jackson, Oates, John A., Linton, MacRae F., Fazio, Sergio, Meador, Beth P., Gross, Myron D., Shyr, Yu, and Morrow, Jason D.
- Subjects
- *
VITAMIN E , *OXIDATIVE stress , *ISOPENTENOIDS , *OXIDATION-reduction reaction - Abstract
Abstract: The oxidation hypothesis of atherogenesis has been the focus of much research over the past 2 decades. However, randomized placebo-controlled trials evaluating the efficacy of vitamin E in preventing cardiovascular events in aggregate have failed to show a beneficial effect. Implicit in these trials is that the dose of vitamin E tested effectively suppressed oxidative stress status but this was never determined. We defined the dose-dependent effects of vitamin E (RRR-α-tocopherol) to suppress plasma concentrations of F2-isoprostanes, a biomarker of free radical-mediated lipid peroxidation, in participants with polygenic hypercholesterolemia and enhanced oxidative stress, a population at risk for cardiovascular events. A time-course study was first performed in participants supplemented with 3200 IU/day of vitamin E for 20 weeks. A dose-ranging study was then performed in participants supplemented with 0, 100, 200, 400, 800, 1600, or 3200 IU/day of vitamin E for 16 weeks. In the time-course study, maximum suppression of plasma F2-isoprostane concentrations did not occur until 16 weeks of supplementation. In the dose-ranging study there was a linear trend between the dosage of vitamin E and percentage reduction in plasma F2-isoprostane concentrations which reached significance at doses of 1600 IU (35±2%, p <0.035) and 3200 IU (49±10%, p <0.005). This study provides information on the dosage of vitamin E that decreases systemic oxidant stress in vivo in humans and informs the planning and evaluation of clinical studies that assess the efficacy of vitamin E to mitigate disease. [Copyright &y& Elsevier]
- Published
- 2007
- Full Text
- View/download PDF
29. Peroxisome proliferator-activated receptor-γ agonist troglitazone protects against nondiabetic glomerulosclerosis in rats.
- Author
-
Ma, Li-Jun, Marcantoni, Carmelita, Linton, Macrae F., Fazio, Sergio, and Fogo, Agnes B.
- Subjects
- *
DIABETES , *INSULIN , *HYPERTENSION , *OBESITY - Abstract
Peroxisome proliferator-activated receptor-γ agonist troglitazone protects against nondiabetic glomerulosclerosis in rats.. Background.: Peroxisome proliferator-activated receptor-γ (PPARγ) is a member of the nuclear receptor superfamily of ligand-dependent transcriptional factors with beneficial effects in diabetes mediated by improved insulin sensitivity and lipid metabolism, but potential adverse effects in atherosclerosis by promoting in vitro foam cell formation. We explored whether a PPARγ agonist, troglitazone (TGL), affects sclerosis by mechanisms unrelated to insulin and lipid effects in a model of nondiabetic glomerulosclerosis. Methods.: Adult male Sprague Dawley rats underwent 5/6 nephrectomy and were treated for 12 weeks as follows: control (CONT), no further treatment; triple antihypertensive therapy (TRX); and TGL or TGL + TRX. Functional, morphological, and molecular analyses were performed. Results.: Systolic blood pressure (SBP) was increased in CONT and TGL groups (161 ± 1 and 160 ± 3 mm Hg), but not in TGL + TRX and TRX (120 ± 3 vs. 126 ± 1 mm Hg, P < 0.0001 vs. non-TRX). Serum triglyceride and cholesterol levels in all groups remained normal except for slightly higher serum cholesterol levels in TRX group. TGL groups had reduced proteinuria, serum creatinine, and glomerulosclerosis versus CONT, in contrast to no significant effect with TRX alone (sclerosis index, 0 to 4+ scale: CONT 1.99 ± 0.42, TGL 0.85 ± 0.12, TGL + TRX 0.56 ± 0.14, TRX 1.30 ± 0.21; TGL, P < 0.05; TGL + TRX, P = 0.01 vs. CONT). Glomerular cell proliferation, assessed by proliferating cell nuclear antigen (PCNA), was decreased after treatment with TGL or TGL + TRX, in parallel with decreases in glomerular p21 mRNA and p27 protein compared with CONT and TRX (PCNA + cells/glomerulus: CONT 2.04 ± 0.64, TGL 0.84 ± 0.21, TGL + TRX 0.30 ± 0.07, TRX 1.38 ± 0.37; TGL, P... [ABSTRACT FROM AUTHOR]
- Published
- 2001
- Full Text
- View/download PDF
30. Myeloperoxidase-induced modification of HDL by isolevuglandins inhibits paraoxonase-1 activity.
- Author
-
Aggarwal, Geetika, May-Zhang, Linda S., Yermalitsky, Valery, Dikalov, Sergey, Voynov, Maxim A., Amarnath, Venkataraman, Kon, Valentina, Linton, MacRae F., Vickers, Kasey C., and Davies, Sean S.
- Subjects
- *
POST-translational modification , *HIGH density lipoproteins , *HYPOCHLORITES , *NITROGEN dioxide , *CATALYTIC activity , *PARAOXONASE - Abstract
Reduced activity of paraoxonase 1 (PON1), a high-density lipoprotein (HDL)-associated enzyme, has been implicated in the development of atherosclerosis. Post-translational modifications of PON1 may represent important mechanisms leading to reduced PON1 activity. Under atherosclerotic conditions, myeloperoxidase (MPO) is known to associate with HDL. MPO generates the oxidants hypochlorous acid and nitrogen dioxide, which can lead to post-translational modification of PON1, including tyrosine modifications that inhibit PON1 activity. Nitrogen dioxide also drives lipid peroxidation, leading to the formation of reactive lipid dicarbonyls such as malondialdehyde and isolevuglandins, which modify HDL and could inhibit PON1 activity. Because isolevuglandins are more reactive than malondialdehyde, we used in vitro models containing HDL, PON1, and MPO to test the hypothesis that IsoLG formation by MPO and its subsequent modification of HDL contributes to MPO-mediated reductions in PON1 activity. Incubation of MPO with HDL led to modification of HDL proteins, including PON1, by IsoLG. Incubation of HDL with IsoLG reduced PON1 lactonase and antiperoxidation activities. IsoLG modification of recombinant PON1 markedly inhibited its activity, while irreversible IsoLG modification of HDL before adding recombinant PON1 only slightly inhibited the ability of HDL to enhance the catalytic activity of recombinant PON1. Together, these studies support the notion that association of MPO with HDL leads to lower PON1 activity in part via IsoLG-mediated modification of PON1, so that IsoLG modification of PON1 could contribute to increased risk for atherosclerosis, and blocking this modification might prove beneficial to reduce atherosclerosis. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
31. Modified sites and functional consequences of 4-oxo-2-nonenal adducts in HDL that are elevated in familial hypercholesterolemia.
- Author
-
May-Zhang, Linda S., Yermalitsky, Valery, Melchior, John T., Morris, Jamie, Tallman, Keri A., Borja, Mark S., Pleasent, Tiffany, Amarnath, Venkataraman, Wenliang Song, Yancey, Patricia G., Davidson, W. Sean, Linton, MacRae F., and Davies, Sean S.
- Subjects
- *
HIGH density lipoproteins , *CHEMICAL adducts , *OMEGA-6 fatty acids , *HYPERCHOLESTEREMIA , *TUMOR necrosis factors , *PROTEIN crosslinking , *UNSATURATED fatty acids - Abstract
The lipid aldehyde 4-oxo-2-nonenal (ONE) is a highly reactive protein crosslinker derived from peroxidation of n-6 polyunsaturated fatty acids and generated together with 4-hydroxynonenal (HNE). Lipid peroxidation product-mediated crosslinking of proteins in high-density lipoprotein (HDL) causes HDL dysfunction and contributes to atherogenesis. AlthoughHNEis relatively well-studied, the role of ONE in atherosclerosis and in modifying HDL is unknown. Here, we found that individuals with familial hypercholesterolemia (FH) had significantly higher ONE-ketoamide (lysine) adducts in HDL (54.6 ± 33.8 pmol/mg) than healthy controls (15.3 ± 5.6 pmol/mg). ONE crosslinked apolipoprotein A-I (apoA-I) on HDL at a concentration of > 3 mol ONE per 10 mol apoA-I (0.3 eq), which was 100-fold lower than HNE, but comparable to the potent protein crosslinker isolevuglandin. ONE-modified HDL partially inhibited HDL's ability to protect against lipopolysaccharide (LPS)-induced tumor necrosis factor α (TNFα) and interleukin-1 (IL-1β) gene expression in murine macrophages. At 3 eq, ONE dramatically decreased apoA-I exchange from HDL, from±46.5 to ±18.4% (p < 0.001). Surprisingly, ONE modification of HDL or apoA-I did not alter macrophage cholesterol efflux capacity. LCMS/MS analysis revealed that Lys-12, Lys-23, Lys-96, and Lys- 226 in apoA-I are modified by ONE ketoamide adducts. Compared with other dicarbonyl scavengers, pentylpyridoxamine (PPM) most efficaciously blocked ONE-induced protein crosslinking in HDL and also prevented HDL dysfunction in an in vitro model of inflammation. Our findings show that ONE-HDL adducts cause HDL dysfunction and are elevated in individuals with FH who have severe hypercholesterolemia. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
32. Modification by isolevuglandins, highly reactive γ-ketoaldehydes, deleteriously alters high-density lipoprotein structure and function.
- Author
-
May-Zhang, Linda S., Yermalitsky, Valery, Davies, Sean S., Linton, MacRae F., Jiansheng Huang, Yancey, Patricia G., Pleasent, Tiffany, Borja, Mark S., Oda, Michael N., and Jerome, W. Gray
- Subjects
- *
HIGH density lipoproteins , *CHOLESTEROL , *LIPOPROTEINS , *CARDIOVASCULAR diseases , *PHOSPHATIDYLETHANOLAMINES , *ATHEROSCLEROSIS - Abstract
Cardiovascular disease risk depends on high-density lipoprotein (HDL) function, not HDL-cholesterol. Isolevuglandins (IsoLGs) are lipid dicarbonyls that react with lysine residues of proteins and phosphatidylethanolamine. IsoLG adducts are elevated in atherosclerosis. The consequences of IsoLG modification of HDL have not been studied. We hypothesized that IsoLG modification of apoA-I deleteriously alters HDL function. We determined the effect of IsoLG on HDL structure-function and whether pentylpyridoxamine (PPM), a dicarbonyl scavenger, can preserveHDL function.IsoLGadducts inHDLderivedfrompatients with familial hypercholesterolemia (n=10, 233.4×158.3 ng/mg) were found to be significantly higher than in healthy controls (n=7, 90.1×33.4 pg/mg protein). Further, HDL exposed to myeloperoxidase had elevated IsoLG-lysine adducts (5.7 ng/mg protein) compared with unexposed HDL (0.5 ng/mg protein). Preincubation with PPM reduced IsoLG-lysine adducts by 67%, whereas its inactive analogue pentylpyridoxine did not. The addition of IsoLG produced apoA-I and apoA-II cross-links beginning at 0.3 molar eq of IsoLG/ mol of apoA-I (0.3 eq), whereas succinylaldehyde and 4-hydroxynonenal required 10 and 30 eq. IsoLG increased HDL size, generating a subpopulation of 16-23 nm. 1 eq of IsoLG decreased HDL-mediated [3H]cholesterol efflux from macrophages via ABCA1, which corresponded to a decrease in HDL-apoA-I exchange from 47.4% to only 24.8%. This suggests that IsoLG inhibits apoA-I from disassociating from HDL to interact with ABCA1. The addition of 0.3 eq of IsoLG ablated HDL's ability to inhibit LPS-stimulated cytokine expression by macrophages and increased IL-1 expression by 3.5-fold. The structural-functional effects were partially rescued with PPM scavenging. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
33. Atherosclerosis following renal injury is ameliorated by pioglitazone and losartan via macrophage phenotype.
- Author
-
Yamamoto, Suguru, Zhong, Jiayong, Yancey, Patricia G., Zuo, Yiqin, Linton, MacRae F., Fazio, Sergio, Yang, Haichun, Narita, Ichiei, and Kon, Valentina
- Subjects
- *
ATHEROSCLEROSIS treatment , *KIDNEY injuries , *PIOGLITAZONE , *LOSARTAN , *PHENOTYPES , *PEROXISOME proliferator-activated receptors - Abstract
Objective Chronic kidney disease (CKD) amplifies atherosclerosis, which involves renin-angiotensin system (RAS) regulation of macrophages. RAS influences peroxisome proliferator-activated receptor-γ (PPARγ), a modulator of atherogenic functions of macrophages, however, little is known about its effects in CKD. We examined the impact of combined therapy with a PPARγ agonist and angiotensin receptor blocker on atherogenesis in a murine uninephrectomy model. Methods Apolipoprotein E knockout mice underwent uninephrectomy (UNx) and treatment with pioglitazone (UNx + Pio), losartan (UNx + Los), or both (UNx + Pio/Los) for 10 weeks. Extent and characteristics of atherosclerotic lesions and macrophage phenotypes were assessed; RAW264.7 and primary peritoneal mouse cells were used to examine pioglitazone and losartan effects on macrophage phenotype and inflammatory response. Results UNx significantly increased atherosclerosis. Pioglitazone and losartan each significantly reduced the atherosclerotic burden by 29.6% and 33.5%, respectively; although the benefit was dramatically augmented by combination treatment which lessened atherosclerosis by 55.7%. Assessment of plaques revealed significantly greater macrophage area in UNx + Pio/Los (80.7 ± 11.4% vs . 50.3 ± 4.2% in UNx + Pio and 57.2 ± 6.5% in UNx + Los) with more apoptotic cells. The expanded macrophage-rich lesions of UNx + Pio/Los had more alternatively activated, Ym-1 and arginine 1-positive M2 phenotypes (Ym-1: 33.6 ± 8.2%, p < 0.05 vs . 12.0 ± 1.1% in UNx; arginase 1: 27.8 ± 0.9%, p < 0.05 vs . 11.8 ± 1.3% in UNx). In vitro , pioglitazone alone and together with losartan was more effective than losartan alone in dampening lipopolysaccharide-induced cytokine production, suppressing M1 phenotypic change while enhancing M2 phenotypic change. Conclusion Combination of pioglitazone and losartan is more effective in reducing renal injury-induced atherosclerosis than either treatment alone. This benefit reflects mitigation in macrophage cytokine production, enhanced apoptosis, and a shift toward an anti-inflammatory phenotype. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
34. Dysfunctional High-Density Lipoprotein in Patients on Chronic Hemodialysis
- Author
-
Yamamoto, Suguru, Yancey, Patricia G., Ikizler, T. Alp, Jerome, W. Gray, Kaseda, Ryohei, Cox, Brian, Bian, Aihua, Shintani, Ayumi, Fogo, Agnes B., Linton, MacRae F., Fazio, Sergio, and Kon, Valentina
- Subjects
- *
HIGH density lipoproteins , *HEMODIALYSIS patients , *CHRONIC diseases , *CHOLESTEROL in the body , *IMMUNOLOGY of inflammation , *KIDNEY diseases , *CARDIOVASCULAR diseases - Abstract
Objectives: This study examined the functionality of high-density lipoprotein (HDL) in individuals with end-stage renal disease on dialysis (ESRD-HD). Background: The high rate of cardiovascular disease (CVD) in chronic kidney disease is not explained by standard risk factors, especially in patients with ESRD-HD who appear resistant to benefits of statin therapy. HDL is antiatherogenic because it extracts tissue cholesterol and reduces inflammation. Methods: Cellular cholesterol efflux and inflammatory response were assessed in macrophages exposed to HDL of patients with ESRD-HD or controls. Results: HDL from patients with ESRD-HD was dramatically less effective than normal HDL in accepting cholesterol from macrophages (median 6.9%; interquartile range [IQR]: 1.4% to 10.2%) versus control (median 14.9%; IQR: 9.8% to 17.8%; p < 0.001). The profound efflux impairment was also seen in patients with ESRD-HD and diabetes compared with patients with diabetes without renal disease (median 8.1%; IQR: 3.3% to 12.9%) versus control (median 13.6%; IQR: 11.0% to 15.9%; p = 0.009). In vitro activation of cellular cholesterol transporters increased cholesterol efflux to both normal and uremic HDL. HDL of patients with ESRD-HD had reduced antichemotactic ability and increased macrophage cytokine response (tumor necrosis factor-alpha, interleukin-6, and interleukin-1-beta). HDL of patients with ESRD-HD on statin therapy had reduced inflammatory response while maintaining impaired cholesterol acceptor function. Interestingly, impaired HDL-mediated efflux did not correlate with circulating C-reactive protein levels or cellular inflammatory response. Conclusions: These findings suggest that abnormal HDL capacity to mediate cholesterol efflux is a key driver of excess CVD in patients on chronic hemodialysis and may explain why statins have limited effect to decrease CV events. The findings also suggest cellular cholesterol transporters as potential therapeutic targets to decrease CV risk in this population. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
35. Novel Domain Interaction Regulates Secretion of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Protein.
- Author
-
&Du, Fen, Hui, Yvonne, Zhang, Michelle, Linton, MacRae F., Fazio, Sergio, and Fan, Daping
- Subjects
- *
SUBTILISINS , *HYPERCHOLESTEREMIA treatment , *LOW density lipoproteins , *MUTAGENESIS , *SECRETION , *DELETION mutation - Abstract
PCSK9 (proprotein convertase subtilisin/kexin type 9) has emerged as a novel therapeutic target for hypercholesterolemia due to its LDL receptor (LDLR)-reducing activity. Although its structure has been solved, the lack of a detailed understanding of the structure-function relation hinders efforts to develop small molecule inhibitors. In this study, we used mutagenesis and transfection approaches to investigate the roles of the prodomain (PD) and the C-terminal domain (CD) and its modules (CM1-3) in the secretion and function of PCSK9. Deletion of PD residues 31-40, 41-50, or 51-60 did not affect the self-cleavage, secretion, or LDLR-degrading activity of PCSK9, whereas deletion of residues 61-70 abolished all of these functions. Deletion of the entire CD protein did not impair PCSK9 self-cleavage or secretion but completely abolished LDLR-degrading activity. Deletion of any one or two of the CD modules did not affect self-cleavage but influenced secretion and LDLR-reducing activity. Furthermore, in cotransfection experiments, a secretion-defective PD deletion mutant (ΔPD) was efficiently secreted in the presence of CD deletion mutants. This was due to the transfer of PD from the cotransfected CD mutants to the ΔPD mutant. Finally, we found that a discrete CD protein fragment competed with full-length PCSK9 for binding to LDLR in vitro and attenuated PCSK9-mediated hypercholesterolemia in mice. These results show a previously unrecognized domain interaction as a critical determinant in PCSK9 secretion and function. This knowledge should fuel efforts to develop novel approaches to PCSK9 inhibition. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
36. Free fatty acids are associated with insulin resistance but not coronary artery atherosclerosis in rheumatoid arthritis
- Author
-
Ormseth, Michelle J., Swift, Larry L., Fazio, Sergio, Linton, MacRae F., Chung, Cecilia P., Raggi, Paolo, Rho, Young Hee, Solus, Joseph, Oeser, Annette, Bian, Aihua, Gebretsadik, Tebeb, Shintani, Ayumi, and Michael Stein, C.
- Subjects
- *
RHEUMATOID arthritis , *ATHEROSCLEROSIS , *FATTY acids , *INSULIN resistance , *CYTOKINES , *METABOLIC syndrome - Abstract
Abstract: Background: Free fatty acids (FFAs) affect insulin signaling and are implicated in the pathogenesis of insulin resistance and atherosclerosis. Inflammatory cytokines such as interleukin-6 (IL-6) increase lipolysis and thus levels of FFAs. We hypothesized that increased IL-6 concentrations are associated with increased FFAs resulting in insulin resistance and atherosclerosis in rheumatoid arthritis (RA). Methods: Clinical variables, serum FFAs and inflammatory cytokines, homeostasis model assessment for insulin resistance (HOMA-IR), and coronary artery calcium were measured in 166 patients with RA and 92 controls. We compared serum FFAs in RA and controls using Wilcoxon rank sum tests and further tested for multivariable association by adjusting for age, race, sex and BMI. Among patients with RA, we assessed the relationship between serum FFAs and inflammatory cytokines, HOMA-IR, and coronary artery calcium scores using Spearman correlation and multivariable regression analyses. Results: Serum FFAs did not differ significantly in patients with RA and controls (0.56mmol/L [0.38–0.75] and 0.56mmol/L [0.45–0.70] respectively, p =0.75). Presence of metabolic syndrome was associated with significantly increased serum FFAs in both RA and controls (p =0.035 and p =0.025). In multivariable regression analysis that adjusted for age, race, sex and BMI, serum FFAs were associated with HOMA-IR (p =0.011), CRP (p =0.01), triglycerides (p =0.005) and Framingham risk score (p =0.048) in RA, but not with IL-6 (p =0.48) or coronary artery calcium score (p =0.62). Conclusions: Serum FFAs do not differ significantly in patients with RA and controls. FFAs may contribute to insulin resistance, but are not associated with IL-6 and coronary atherosclerosis in RA. [Copyright &y& Elsevier]
- Published
- 2011
- Full Text
- View/download PDF
37. Mechanism of Down-regulation of RNA Polymerase III-transcribed Non-coding RNA Genes in Macrophages by Leishmania.
- Author
-
Rana, Tanu, Misra, Smita, Mittal, Mukul K., Farrow, Anitra L., Wilson, Keith T., Linton, MacRae F., Fazio, Sergio, Willis, Ian M., and Chaudhuri, Gautam
- Subjects
- *
RNA polymerases , *NON-coding RNA , *MACROPHAGES , *LEISHMANIA , *PROTEOLYTIC enzymes , *THROMBIN , *TARGETED drug delivery - Abstract
The parasitic protozoan Leishmania invades mammalian macrophages to establish infection. We reported previously that Leishmania manipulates the expression of several non-coding RNA genes (e.g. Alu RNA, B1 RNA, and signal recognition particle RNA) in macrophages to favor the establishment of their infection in the phagolysosomes of these cells (Ueda, Y., and Chaudhuri, G. (2000) J. Biol. Chem. 275, 19428-19432; Misra, S., Tripathi, M. K., and Chaudhuri, G. (2005) J. Biol. Chem. 280, 29364-29373). We report here the mechanism of this down-regulation. We found that the non-coding RNA (ncRNA) genes that are repressed by Leishmania infection in macrophages contain a "B-box" in their promoters and thus require the polymerase III transcription factor TFIIIC for their expression. We also found that Leishmania promastigotes through their surface protease (leishmanolysin or gp63) activate the thrombin receptor PAR1 in the macrophages. This activation of PAR1 raised the cytosolic concentration of Ca2+ into the micromolar range, thereby activating the Ca2+-dependent protease μ-calpain. μ-Calpain then degraded TFIIIC110 to inhibit the expression of the selected ncRNA genes. Avirulent stocks of Leishmania not expressing surface gp63 failed to down-regulate ncRNAs in the exposed macrophages. Inhibition of PAR1 or calpain 1 in macrophages made them resistant to Leishmania infection. These data suggest that macrophage PAR1 and calpain 1 are potential drug targets against leishmaniasis. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
38. Selective macrophage ascorbate deficiency suppresses early atherosclerosis
- Author
-
Babaev, Vladimir R., Whitesell, Richard R., Li, Liying, Linton, MacRae F., Fazio, Sergio, and May, James M.
- Subjects
- *
VITAMIN C deficiency , *FETAL liver cells , *APOPTOSIS , *APOLIPOPROTEIN E , *MACROPHAGES , *CELL transplantation , *LABORATORY mice ,ANIMAL models of atherosclerosis - Abstract
Abstract: To test whether severe ascorbic acid deficiency in macrophages affects progression of early atherosclerosis, we used fetal liver cell transplantation to generate atherosclerosis-prone apolipoprotein E-deficient (apoE−/−) mice that selectively lacked the ascorbate transporter (SVCT2) in hematopoietic cells, including macrophages. After 13weeks of chow diet, apoE−/− mice lacking the SVCT2 in macrophages had surprisingly less aortic atherosclerosis, decreased lesion macrophage numbers, and increased macrophage apoptosis compared to control-transplanted mice. Serum lipid levels were similar in both groups. Peritoneal macrophages lacking the SVCT2 had undetectable ascorbate; increased susceptibility to H2O2-induced mitochondrial dysfunction and apoptosis; decreased expression of genes for COX-2, IL1β, and IL6; and decreased lipopolysaccharide-stimulated NF-κB and antiapoptotic gene expression. These changes were associated with decreased expression of both the receptor for advanced glycation end products and HIF-1α, either or both of which could have been the proximal cause of decreased macrophage activation and apoptosis in ascorbate-deficient macrophages. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
39. Overexpression of Human Apolipoprotein A-I Preserves Cognitive Function and Attenuates Neuroinflammation and Cerebral Amyloid Angiopathy in a Mouse Model of Alzheimer Disease.
- Author
-
Lewis, Terry L., Dongfeng Cao, Hailin Lu, Mans, Robert A., Yan Ru Su, Lisa Jungbauer, Linton, MacRae F., Fazio, Sergio, LaDu, Mary Jo, and Ling Li
- Subjects
- *
APOLIPOPROTEINS , *CEREBRAL amyloid angiopathy , *AGE factors in cognition , *ANIMAL models of Alzheimer's disease , *HIGH density lipoproteins , *CARDIOVASCULAR diseases risk factors , *TRANSGENIC mice - Abstract
To date there is no effective therapy for Alzheimer disease (AD). High levels of circulating high density lipoprotein (HDL) and its main protein, apolipoprotein A-I (apoA-I), reduce the risk of cardiovascular disease. Clinical studies show that plasma HDL cholesterol and apoA-I levels are low in patients with AD. To investigate if increasing plasma apoA-I/HDL levels ameliorates AD-like memory deficits and amyloid-β (Aβ) deposition, we generated a line of triple transgenic (Tg) mice overexpressing mutant forms of amyloid-β precursor protein (APP) and presenilin 1 (PS1) as well as human apoA-I (AI). Here we show that APP/PS1/AI triple Tg mice have a 2-fold increase of plasma HDL cholesterol levels. When tested in the Morris water maze for spatial orientation abilities, whereas APP/PS1 mice develop age-related learning and memory deficits, APP/PS1/AI mice continue to perform normally during aging. Interestingly, no significant differences were found in the total level and deposition of Aβ in the brains of APP/PS1 and APP/PS1/AI mice, but cerebral amyloid angiopathy was reduced in APP/PS1/AI mice. Also, consistent with the anti-inflammatory properties of apoA-I/HDL, glial activation was reduced in the brain of APP/PS1/AI mice. In addition, Aβ-induced production of proinflammatory chemokines/cytokines was decreased in mouse organotypic hippocampal slice cultures expressing human apoA-I. Therefore, we conclude that overexpression of human apoA-I in the circulation prevents learning and memory deficits in APP/PS1 mice, partly by attenuating neuroinflammation and cerebral amyloid angiopathy. These findings suggest that elevating plasma apoA-I/HDL levels may be an effective approach to preserve cognitive function in patients with AD. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
40. A practical approach to risk assessment to prevent coronary artery disease and its complications.
- Author
-
Linton MF, Fazio S, Linton, MacRae F, Fazio, Sergio, and National Cholesterol Education Program (NCEP)- the third Adult Treatment Panel (ATP III)
- Abstract
The recent focus on emerging cardiovascular risk factors, such as C-reactive protein, homocysteine, and small, dense low-density lipoprotein (LDL), may give the false impression that the current approach to the assessment of cardiovascular disease risk fails to identify a large section of the high-risk population. On the contrary, the new guidelines of the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) propose classifying an enormous number of individuals, including people with any form of atherosclerotic disease, diabetes, and a combination of major risk factors, into the category of high risk (>20% likelihood of a major coronary event or stroke in 10 years). Considering the widespread prevalence of the metabolic syndrome-a high-risk condition characterized by mild hypertension, mild dyslipidemia, hyperglycemia, and visceral obesity-we may be faced with the challenge of implementing aggressive risk reduction therapies in as much as 30% of the adult US population. From the point of view of risk assessment, a practical approach is to follow the NCEP guidelines (ie, place patients with diabetes and those with atherosclerotic complications in the highest risk category), apply the Framingham calculation to determine risk in people with common risk factors, and initiate early intervention in people who have familial hypercholesterolemia (LDL cholesterol >200 mg/dL) or a family history of early cardiovascular disease. The emerging risk factors may be useful for further stratifying risk in individuals with intermediate risk and the presence of risk factors not included in the Framingham calculation. [ABSTRACT FROM AUTHOR]
- Published
- 2003
- Full Text
- View/download PDF
41. Impaired Secretion of Apolipoprotein E2 from Macrophages.
- Author
-
Daping Fan, Shenfeng Qiu, Overton, Cheryl D., Yancey, Patricia G., Swift, Larry L., Jerome, W. Gray, Linton, MacRae F., and Fazio, Sergio
- Subjects
- *
APOLIPOPROTEIN E , *MACROPHAGES , *LIVER cells , *BRAIN , *ISOPENTENOIDS - Abstract
Human apoE is a multifunctional and polymorphic protein synthesized and secreted by liver, brain, and tissue macrophages. Here we show that apoE isoforms and mutants expressed through lentiviral transduction display cell-specific differences in secretion efficiency. Whereas apoE3, apoE4, and a natural mutant of apoE4 (apoE-Cys142) were efficiently secreted from macrophages, apoE2 and a non-natural apoE mutant (apoE-Cys112/Cys142) were retained in the perinuclear region and only minimally secreted. The secretory block for apoE2 in macrophages was not affected by the ablation of LDLR (low density lipoprotein receptor), ABCA-1, or SR-BI (scavenger receptor class B type 1) but was released in the absence of low density lipoprotein receptor-related protein (LRP). In co-immunoprecipitation experiments, an anti-apoE antibody pulled down two times more LRP in apoE2-transduced macrophages than in apoE3-expressing macrophages. Non-reducing SDS-PAGE/Western blot analyses showed that macrophage apoE2 is mostly dimeric and multimeric, whereas apoE3 is predominantly monomeric. ApoE2 retention and multimer formation also occurred in human macrophages derived from the monocyte cell line THP-1. These results were specific for macrophages, as in transduced mouse primary hepatocytes: 1) ApoE2 was secreted as efficiently as apoE3 and apoE4; 2) all isoforms were exclusively in monomeric form; 3) there was no co-immunoprecipitation of apoE and LRP. A microsomal triglyceride transfer protein (MTP) inhibitor nearly deleted apoB100 secretion from hepatocytes without affecting apoE secretion. These data show that macrophages retain apoE2, a highly expressed protein carried by about 8% of the human population. Given the role of locally produced apoE in regulating cholesterol efflux, modulating inflammation, and controlling oxidative stress, this unique property of apoE2 may have important impacts on atherogenesis. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
42. ACAT1 deficiency increases cholesterol synthesis in mouse peritoneal macrophages
- Author
-
Dove, Dwayne E., Su, Yan Ru, Swift, Larry L., Linton, MacRae F., and Fazio, Sergio
- Subjects
- *
COENZYMES , *ACYLTRANSFERASES , *CHOLESTEROL , *HYPERLIPIDEMIA - Abstract
Abstract: Acyl-coenzyme A: cholesterol acyltransferase (ACAT) esterifies free cholesterol and stores cholesteryl esters in lipid droplets. Macrophage ACAT1 deficiency results in increased atherosclerotic lesion area in hyperlipidemic mice via disrupted cholesterol efflux, increased lipoprotein uptake, accumulation of intracellular vesicles, and accelerated apoptosis. The objective of this study was to determine whether lipid synthesis is affected by ACAT1. The synthesis, esterification, and efflux of new cholesterol were measured in peritoneal macrophages from ACAT1(−/−) mice. Cholesterol synthesis was increased by 134% (p =0.001) in ACAT1(−/−) macrophages compared to wildtype macrophages. Increased synthesis resulted in a proportional increase in the efflux of newly synthesized cholesterol. Although the esterification of new cholesterol was reduced by 93% (p <0.001) in ACAT1(−/−) macrophages, trace amounts of newly synthesized cholesteryl esters were detectable. Furthermore, the expression of SREBP1a mRNA was increased 6-fold in ACAT1(−/−) macrophages compared to wildtype macrophages, suggesting an up-regulation of cholesterol and fatty acid synthesis in ACAT1(−/−) macrophages. Increased cholesterol synthesis and up-regulation of SREBP in ACAT1(−/−) macrophages suggests that ACAT1 affects the regulation of lipid metabolism in macrophages. This change in cholesterol homeostasis may contribute to the atherogenic potential of ACAT1(−/−) macrophages. [Copyright &y& Elsevier]
- Published
- 2006
- Full Text
- View/download PDF
43. Transiently heightened angiotensin II has distinct effects on atherosclerosis and aneurysm formation in hyperlipidemic mice
- Author
-
Ayabe, Nobuhiko, Babaev, Vladimir R., Tang, YiWei, Tanizawa, Takakuni, Fogo, Agnes B., Linton, MacRae F., Ichikawa, Iekuni, Fazio, Sergio, and Kon, Valentina
- Subjects
- *
ATHEROSCLEROSIS , *ANEURYSMS , *ATHEROSCLEROTIC plaque , *MESSENGER RNA - Abstract
Abstract: Experimentally sustained increase in angiotensin II (AngII) promotes tissue destruction in various cardiovascular disorders. We examined whether transiently heightened AngII affects subsequent atherosclerosis and aneurysm formation. AngII or saline was administered for 2 weeks to apolipoprotein E (apoE)-deficient mice. Mice were sacrificed at the end of the 2-week infusion or 6- or 14 weeks later. Short-term AngII did not affect atherosclerosis immediately following the infusion or 6 weeks later. By contrast, 14 weeks after infusion there was remarkably more atherosclerosis in previously AngII-exposed mice. Preceding the build up of atherosclerotic lesions, AngII-exposure increased mRNA expression and immunostaining of monocyte chemoattractant protein-1 (MCP-1) and its receptor, CCR2. This was followed by greater macrophage-positivity in AngII-exposed aortae. In contrast to the delayed effects on atherosclerosis, 20% of mice were found to have abdominal aneurysms at the end of AngII-exposure. This effect was not contingent on blood pressure. Moreover, despite amplification in atherosclerosis following AngII, no aneurysms were found 14 weeks later. Our studies reveal that even transient exposure to AngII primes the vessel for subsequent amplification of atherosclerosis which involves activation of MCP-1/CCR2 and influx of macrophages into the nascent atherosclerotic plaque. By contrast, transient AngII-exposure causes prompt aneurysm formation that does not parallel atherosclerosis and disappears even in the face of progressively greater atherosclerotic lesions. [Copyright &y& Elsevier]
- Published
- 2006
- Full Text
- View/download PDF
44. Inhibition of cyclooxygenase with indomethacin phenethylamide reduces atherosclerosis in apoE-null mice
- Author
-
Burleigh, Michael E., Babaev, Vladimir R., Patel, Mayur B., Crews, Brenda C., Remmel, Rory P., Morrow, Jason D., Oates, John A., Marnett, Lawrence J., Fazio, Sergio, and Linton, MacRae F.
- Subjects
- *
APOLIPOPROTEIN E , *ATHEROSCLEROSIS , *RODENTS , *INDOMETHACIN - Abstract
Abstract: Non-selective inhibition of cyclooxygenase (COX) has been reported to reduce atherosclerosis in both rabbit and murine models. In contrast, selective inhibition of COX-2 has been shown to suppress early atherosclerosis in LDL-receptor null mice but not more advanced lesions in apoE deficient (apoE−/−) mice. We investigated the efficacy of the novel COX inhibitor indomethacin phenethylamide (INDO-PA) on the development of different stages of atherosclerotic lesion formation in female apoE−/− mice. INDO-PA, which is highly selective for COX-2 in vitro, reduced platelet thromboxane production by 61% in vivo, indicating partial inhibition of COX-1 in vivo. Treatment of female apoE−/− mice with 5mg/kg INDO-PA significantly reduced early to intermediate aortic atherosclerotic lesion formation (44 and 53%, respectively) in both the aortic sinus and aorta en face compared to controls. Interestingly, there was no difference in the extent of atherosclerosis in the proximal aorta in apoE−/− mice treated from 11 to 21 weeks of age with INDO-PA, yet there was a striking (76%) reduction in lesion size by en face analysis in these mice. These studies demonstrate the ability of non-selective COX inhibition with INDO-PA to reduce early to intermediate atherosclerotic lesion formation in apoE−/− mice, supporting a role for anti-inflammatory approaches in the prevention of atherosclerosis. [Copyright &y& Elsevier]
- Published
- 2005
- Full Text
- View/download PDF
45. Macrophage apolipoprotein A-I expression protects against atherosclerosis in ApoE-Deficient mice and up-regulates ABC transporters
- Author
-
Ru Su, Yan, Ishiguro, Hiroyuki, Major, Amy S., Dove, Dwayne E., Zhang, Wenwu, Hasty, Alyssa H., Babaev, Vladimir R., Linton, MacRae F., and Fazio, Sergio
- Subjects
- *
MACROPHAGES , *LIPOPROTEINS , *CHOLESTEROL - Abstract
The antiatherogenic effect of high-density lipoprotein (HDL) and its major protein component apolipoprotein A-I (apoA-I) has been largely attributed to their key roles in reverse cholesterol transport (RCT) and cellular cholesterol efflux. Substantial evidence shows that overexpression of human apoA-I reduces atherosclerosis in animal models. However, it is uncertain whether this protection is due to an increase in plasma HDL level or to a local effect in the artery wall. To test the hypothesis that expression of human apoA-I in macrophages can promote RCT in the artery wall, we used a retroviral construct expressing human apoA-I cDNA (MFG-HAI) to transduce ApoE−/− bone marrow cells and then transplanted these cells into ApoE−/− mice with preexisting atherosclerosis. ApoE−/− mice reconstituted with MFG-HAI marrow had a significant reduction (30%) in atherosclerotic lesions in the proximal aorta compared to control mice that received marrow expressing MFG parental virus. Peritoneal macrophages isolated from MFG-HAI mice showed a four- to fivefold increase in mRNA expression levels of both ATP-binding cassette (ABC) A1 and ABCG1 compared to controls. Our data demonstrate that gene transfer-mediated expression of human apoA-I in macrophages can compensate in part for apoE deficiency and delay the progression of atherosclerotic lesions by stimulating ABC-dependent cholesterol efflux and RCT. [Copyright &y& Elsevier]
- Published
- 2003
- Full Text
- View/download PDF
46. Hepatocyte-derived ApoE Is More Effective than Non-hepatocyte-derived ApoE in Remnant Lipoprotein Clearance.
- Author
-
Raffaï, Robert L., Hasty, Alyssa H., Yuwei Wang, Mettler, Shelley E., Sanan, David A., Linton, MacRae F., Fazio, Sergio, and Weisgraber, Karl H.
- Subjects
- *
APOLIPOPROTEIN E , *LIVER cells - Abstract
Addresses the controversy concerning the importance of both hepatically derived and localized apolipoprotein E (apoE) in remnant clearance in in vivo models. Assessment of remnant clearance in hypoE mice; Presence of detectable levels of apoE on hepatic sinusoidal surfaces in the hepatocyte-derived apoE model; Enrichment of remnants sequestered on hepatocyte.
- Published
- 2003
47. The Recycling of Apolipoprotein E in Primary Cultures of Mouse Hepatocytes.
- Author
-
Farkas, Monica H., Swift, Larry L., Hasty, Alyssa H., Linton, MacRae F., and Fazio, Sergio
- Subjects
- *
APOLIPOPROTEIN E , *LIVER cells - Abstract
Describes the recycling of apolipoprotein E (apoE) in primary cultures of mouse hepatocytes. Internalization of apoE-containing very low density protein (VLDL) by hepatocytes in vitro and in vivo; Increase in the mass of apoE; Detection of intact intracellular apoE.
- Published
- 2003
- Full Text
- View/download PDF
48. Proprotein convertase subtilisin/kexin type 9 as transducer of physiologic influences on cellular cholesterol: a case for resistin.
- Author
-
Fazio S, Linton MF, Fazio, Sergio, and Linton, MacRae F
- Published
- 2012
- Full Text
- View/download PDF
49. Low levels of high-density lipoprotein cholesterol due to lecithin:cholesterol acyltransferase mutations increase carotid atherosclerosis.
- Author
-
Fazio S, Linton MF, Fazio, Sergio, and Linton, MacRae F
- Published
- 2011
- Full Text
- View/download PDF
50. INITIAL RESULTS FROM THE CASCADE-FH REGISTRY: CASCADE SCREENING FOR AWARENESS AND DETECTION OF FAMILIAL HYPERCHOLESTEROLEMIA.
- Author
-
O’Brien, Emily Claire, DeGoma, Emil, Moriarty, Patrick, Linton, MacRae F., Shapiro, Michael, Duell, Bart, Ballantyne, Christie, Neal, William, Ahmad, Zahid, Duffy, Danielle, Hudgins, Lisa, Hemphill, Linda, Underberg, James, Watson, Karol, Gidding, Samuel, Baum, Seth, Dilzell, Kristen, Ross, Joyce, Pickhardt, David, and Kindt, Iris
- Subjects
- *
HYPERCHOLESTEREMIA diagnosis , *MEDICAL registries , *LOW density lipoproteins , *FOLLOW-up studies (Medicine) , *HYPERCHOLESTEREMIA treatment - Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.